Plasma amyloid-β in patients with tangier disease

Journal of Alzheimer's Disease

Volumn 35, Issue 2, 2013, Pages 307-312

  Shahim, Pashtun ^a   Mattsson, Niklas ^a   Lautner, Ronald ^a   Blennow, Kaj ^a   Hovingh, G Kees ^b   Motazacker, M Mahdi ^b   Zetterberg, Henrik ^a,c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid ; biological markers; plasma; Tangier disease

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[X-40]; AMYLOID BETA PROTEIN[X-42]; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TANGIER DISEASE;

EID: 84877134978     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122425     Document Type: Article

References (41)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112-2117.
3. Sparks DL, Scheff SW, Hunsaker JC, 3rd, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-Amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126, 88-94.
4. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA (2010) Association of higher levels of highdensity lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol 67, 1491-1497.
5. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249.
6. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041.
7. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
8. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A 105, 14052-14057.
9. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL (2008) Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71, 85-92.
10. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein e and apolipoprotein e receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006312.
11. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE (1998) Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252, 711-715.
12. Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8, 1-21.
13. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM (2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280, 43236-43242.
14. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL (2004) Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 279, 41197-41207.
15. Burns MP, Vardanian L, Pajoohesh-Ganji A,Wang L, Cooper M, Harris DC, Duff K, Rebeck GW (2006) The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J Neurochem 98, 792-800.
16. Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12, 105-112.
17. Ladu MJ, Reardon C, Van Eldik L, Fagan AM, Bu G, Holtzman D, Getz GS (2000) Lipoproteins in the central nervous system. Ann N Y Acad Sci 903, 167-175.
18. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, HahmannHW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22, 347-351.
19. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G (1999) Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22, 352-355.
20. Koldamova R, Staufenbiel M, Lefterov I (2005) Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280, 43224-43235.
21. Hicks DA, Nalivaeva NN, Turner AJ (2012) Lipid rafts and Alzheimer's disease: Protein-lipid interactions and perturbation of signaling. Front Physiol 3, 189.
22. Katzov H, Chalmers K, Palmgren J, Andreasen N, Johansson B, Cairns NJ, Gatz M, Wilcock GK, Love S, Pedersen NL, Brookes AJ, BlennowK,Kehoe PG, Prince JA(2004) Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-Amyloid metabolism. Hum Mutat 23, 358-367.
23. Li Y, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Schrodi S, Leong D, Lau K, Catanese J, Sninsky J,Nowotny P, Holmans P, Hardy J, Powell J, Lovestone S, Thal L, Owen M, Williams J, Goate A, Grupe A (2004) Association of ABCA1 with late-onset Alzheimer's disease is not observed in a casecontrol study. Neurosci Lett 366, 268-271.
24. Jiang M, Lv L, Wang H, Yang X, Ji H, Zhou F, Zhu W, Cai L, Gu X, Sun J, Dong Q (2012) Meta-Analysis on association between the ATP-binding cassette transporter A1 gene (ABCA1) and Alzheimer's disease. Gene 510, 147-153.
25. Puntoni M, Sbrana F, Bigazzi F, Sampietro T (2012) Tangier disease: Epidemiology, pathophysiology, and management. Am J Cardiovasc Drugs 12, 303-311.
26. Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, Koldamova R (2012) Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-Targeted replacement mice. J Neurosci 32, 13125-13136.
27. Koldamova RP, Lefterov IM, Staufenbiel M,Wolfe D, Huang S, Glorioso JC,Walter M, Roth MG, Lazo JS (2005) The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 280, 4079-4088.
28. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-367.
29. Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ (2001) Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis 156, 217-225.
30. Schaefer EJ, Santos RD, Asztalos BF (2010) Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol 21, 289-297.
31. Breteler MM (2000) Vascular risk factors for Alzheimer's disease: An epidemiologic perspective. Neurobiol Aging 21, 153-160.
32. Merched A, Xia Y, Visvikis S, Serot JM, Siest G (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 21, 27-30.
33. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137, 149-155.
34. Wollmer MA, Streffer JR, Lutjohann D, Tsolaki M, Iakovidou V, Hegi T, Pasch T, Jung HH, Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A (2003) ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24, 421-426.
35. Karasinska JM, Rinninger F, Lutjohann D, Ruddle P, Franciosi S, Kruit JK, Singaraja RR, Hirsch-Reinshagen V, Fan J, Brunham LR, Bissada N, Ramakrishnan R, Wellington CL, Parks JS, Hayden MR (2009) Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J Neurosci 29, 3579-3589.
36. Fagan AM, Christopher E, Taylor JW, Parsadanian M, Spinner M, Watson M, Fryer JD, Wahrle S, Bales KR, Paul SM, Holtzman DM (2004) ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloidbeta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol 165, 1413-1422.
37. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118, 671-682.
38. Koldamova R, Fitz NF, Lefterov I (2010) The role of ATPbinding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim Biophys Acta 1801, 824-830.
39. Koudinov A, Matsubara E, Frangione B, Ghiso J (1994) The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 205, 1164-1171.
40. Hovingh GK, Kuivenhoven JA, Bisoendial RJ, Groen AK, van Dam M, van Tol A, Wellington C, Hayden MR, Smelt AH, Kastelein JJ (2004) HDL deficiency and atherosclerosis: Lessons from Tangier disease. J Intern Med 255, 299-301.
41. Candini C, Schimmel AW, Peter J, Bochem AE, Holleboom AG, Vergeer M, Dullaart RP, Dallinga-Thie GM, Hovingh GK, Khoo KL, Fasano T, Bocchi L, Calandra S, Kuivenhoven JA, Motazacker MM (2010) Identification and characterization of novel loss of function mutations in ATPbinding cassette transporter A1 in patients with low plasma high-density lipoprotein cholesterol. Atherosclerosis 213, 492-498.